Loading data for ABUS — first visit, this takes a few seconds.
Arbutus Biopharma Corporation (ABUS)
NasdaqGS: ABUS
· 即時價格 · USD
5.20
+0.02 (0.39%)
收盤價： Sep 11, 2026, 2:07 PM
股價、關鍵數字和最新消息，都在這一頁。
Arbutus Biopharma Corporation（ABUS）股價、分析與資料
無可用資料
| 買價 | 5.18 |
| 市值 | 1.02B |
| 營收 (ttm) | 182M |
| 淨利（ttm） | 153M |
| 0.62 | |
| 0.79 | |
| 6.53 | |
| -31.22 | |
| P/B (ttm) | 3.94 |
| P/S (ttm) | 5.63 |
| 財報日期 | Nov 16, 2026 |
| 賣價 | 6.5 |
| 成交量 | 502,157 |
| 20 日平均成交量 | 3,017,875 |
| 開盤價 | 5.16 |
| 前收盤價 | 5.18 |
| 當日區間 | 5.15 - 5.23 |
| 52 週範圍 | 3.50 - 5.45 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ABUS
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1...
完整的公司簡介財報驚奇
Arbutus Biopharma 已於 Aug 12, 2026 公布季度財報：
- 營收為 $179.13M 低於預期 $0, 年增 10054.54% 成長.
- 每股盈餘為 -0.04 低於預期 -0.01, 年增 -500.00% 下滑.
第 1 頁，共 2 頁